NanoVation Therapeutics is a pioneer in the design and creation of lipid nanoparticles (LNPs) for nucleic acid delivery. The company’s LNP technologies aim to overcome the limitations of existing nucleic acid delivery approaches, including the ability to target tissues outside the liver (extrahepatic delivery).
NanoVation’s lead technology is its proprietary long-circulating LNP (lcLNP™) platform, which enables functional nucleic acid delivery to extrahepatic cell types and has demonstrated an improved therapeutic index in preclinical studies.
NanoVation partners with leading pharmaceutical and biotech companies develop genetic medicines for previously untreatable diseases.
NVTx is delivering tomorrow's genetic medicines, today.
For more information, please visit nanovationtx.com.
Company Details
- Employees
- 47
- Founded
- -
- Address
- 2665 East Mall, Vancouver,british Columbia V6t 1z4,canada
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.nanovationtx.com
- Keywords
- lipid nanoparticles.
- HQ
- Vancouver, British Columbia
Nanovation Therapeutics™ Questions
Nanovation Therapeutics™'s website is http://www.nanovationtx.com
Nanovation Therapeutics™'s LinkedIn profile is https://ca.linkedin.com/company/nanovationtx
Nanovation Therapeutics™ has
47 employees.
View email and phone details for 47
employees at Nanovation Therapeutics™.
Nanovation Therapeutics™'s industry is
Biotechnology Research
Nanovation Therapeutics™'s top competitors are
Xenon Pharmaceuticals Inc.,
Aspect Biosystems,
Stemcell Technologies,
Zymeworks Inc.,
Nuvalent, Inc.,
Admare Bioinnovations,
Novo Nordisk,
Acuitas Therapeutics,
Gc Therapeutics,
Abcellera.
Nanovation Therapeutics™'s categories are Biotechnology Research
Nanovation Therapeutics™'s founding year is 2020
